Metastasis in Medical Technology

Mayo Clinic Study Shows Drug Could Effectively Treat, Prevent the Spread of Breast Cancer

... for controlling tumor growth, metastasis to bone and bone disorders," such as osteolysis ... as a therapeutic agent to target primary tumors, metastasis to bone and tumor-induced osteolysis. There are ... cancer. "Targeting metastatic tumors at sites of metastasis would be of great benefit for patients who have ...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

... nimotuzumab in combination with radiation. These two indications - brain metastasis from lung cancer and palliative therapy in non-small cell lung cancer ... of high unmet need. In the US, approximately 140,000 cases of brain metastasis are diagnosed annually and the frequency is increasing as more patients ...

Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

... cancer of unknown primary (CUP). Accurately identifying the origin of a metastasis can be critical in guiding treatment decisions. Rosetta Genomics' ... 8:00AM - 12:00PM; Hall S102a; abstract # 11026. The distinction of liver metastasis from hepatocellular carcinoma (HCC) and determining its tissue origin is a ...

Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint

... cardiovascular disease, HIV, renal ischemic disease, and prevention of metastasis in oncology. About Mozobil Mozobil, a novel small molecule CXCR4 ... arterial disease, HIV, renal ischemic disease, and prevention of metastasis in oncology. These statements are subject to risks and uncertainties that ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... Capanna R, Coia LR, Coleman R. et al. eds. Textbook of Bone Metastases. Hoboken, NJ: Edition: John Wiley and Sons; 2005:105. (2) Mundy GR. metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer . 2002 Aug;2(8):584-93. (3) Schulman K and Kohles J. Cancer. ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... Capanna R, Coia LR, Coleman R. et al. eds. Textbook of Bone Metastases. Hoboken, NJ: Edition: John Wiley and Sons; 2005:105. (2) Mundy GR. metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer . 2002 Aug;2(8):584-93. (3) Schulman K and Kohles J. Cancer. ...

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

... needed more than ever," says Roel Schaapveld, Chief Executive Officer, InteRNA. There is a large body of evidence indicating that tumor growth and metastasis formation are dependent on the formation of new blood vessels. Furthermore, angiogenesis is an early event in the development of tumors, being ...

/C O R R E C T I O N -- Agendia B.V./

... addressing the panel's recommendations. The FDA-cleared assay is always clinically useful and indicates whether a patient is at low or high risk for metastasis and the resulting clarity is vital in helping physicians personalize treatment options. "St. Gallen's guideline inclusion is a key step in ...

Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations

... addressing the panel's recommendations. The FDA-cleared assay is always clinically useful and indicates whether a patient is at low or high risk for metastasis and the resulting clarity is vital in helping physicians personalize treatment options. "St. Gallen's guideline inclusion is a key step in ...

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

... confirmed, locally advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastasis received weekly paclitaxel poliglumex (50mg/m2) and cisplatin 25mg/m2 for six weeks with concurrent 50.5Gy of radiation. Twenty-three eligible ...

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

... origin is critical for determining optimal treatment, enabling better patient outcomes. Current diagnostic methods to identify the origin of a metastasis include a range of costly, time-consuming and at times inefficient tests. miRview(TM) mets offers physicians a fast, accurate and easy-to-interpret ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

... patients will develop metastases during the course of their disease. The only chance of long-term survival comes with curative resection of hepatic metastasis by liver surgery with reported five and 10 year survival rates of 41 percent and 22 percent, respectively. Previous trials of combination ...

Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps

... bone metastases can eventually cause the bone to fracture and seriously affect a patient's quality of life. Each year, about 100,000 cases of bone metastasis are reported in the United States. In treating cancer patients with painful bone metastases, interventional radiologists may also use ...

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

... survival was defined as the length of time after randomization during which patients had no local recurrence, contralateral breast cancer, distant metastasis and/or secondary carcinoma. Exploratory endpoints included bone metastasis-free survival(1). At the median follow-up of 48 months, disease-free ...

Research Teams at J. Craig Venter Institute and Ludwig Institute for Cancer Research Uncover New Chromosomal Alterations in Cancer Using Transcriptome Sequencing Approach

... According to Andrew Simpson, Ph.D., Scientific Director of the LICR, "These studies are an important component of the Hilton-Ludwig Cancer metastasis Initiative, focused on preventing and treating cancer metastasis. This program brings together interdisciplinary teams of expert scientists, working ...

Micromet Key Events for 2009

... to start a randomized, controlled, multicenter phase 2 clinical trial in relapsed colorectal cancer patients after complete resection of liver metastasis in Q1 2009; -- Blinatumomab, a CD19-targeting BiTE antibody in development with MedImmune, is expected to start an additional phase 2 clinical ...

Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

... analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis - those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy ...

Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

... analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis - those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy ...

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

... The non-HA-producing xenograft Du145luc model was utilized in a similar manner with docetaxel. Finally, an HA-producing PC3-M-luc disseminated bone metastasis model was used to test PEGPH20 alone and in combination with docetaxel. Xenograft PC3 results -- Tumor volume growth suppressed significantly. ...

First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval

... adenocarcinomas that either arise in the lung or spread to the lung and pleura from other sites. Another test is designed to identify the origin of a metastasis in patients presenting with cancer of unknown primary (CUP). About microRNAs MicroRNAs (miRNAs) are recently discovered, naturally occurring, ...

Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain

... Tumors From Metastases in the Brain With Accuracy Near 90% Identifying Whether a Brain Malignancy is a Primary Tumor or a metastasis is a Recurring Challenge for Pathologists Using Current Technologies Accurately Differentiating Primary From Metastatic Tumors is Critical for ...

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

... arm, two patients had confirmed partial response and four patients had long disease stabilization, including complete disappearance of brain metastasis in one patient. The most commonly reported adverse events were neutropenia and mouth sores. "These preliminary results are very exciting given that ...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

... Number 2551: Yi Yin, Philip E. Thorpe. Combination of a monoclonal anti-phosphatidylserine antibody with docetaxel strongly inhibits the growth and metastasis of hormone-refractory prostate cancers in mice, UT Southwestern Medical Center, Dallas, TX, April 14, 2008, 2:10 PM - 2:25 PM About Peregrine ...

PG500 Series Presented at the AACR Annual Meeting in San Diego

... of cancer. The data presented shows that this series of heparan sulfate mimetic compounds have very strong inhibition of angiogenesis and metastasis and strong anti-tumor activity in some aggressive tumor models. The data firmly supports the continued pre-clinical development of this new series ...

Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica

... adenocarcinomas that either arise in the lung or spread to the lung and pleura from other sites. Another test is designed to identify the origin of a metastasis in patients presenting with cancer of unknown primary (CUP) origin. About microRNAs MicroRNAs (miRNAs) are recently discovered, naturally ...

Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer

... sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In April 2007, data from a randomised phase 2 trial in the ...

Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium

... sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. This press release contains forward-looking statements ...

Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer

... sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In April 2007, data from a randomized phase II trial in ...

Anastrozole Confirmed Superior in Breast Cancer Prevention

... 10 years (5 years after the completion of treatment), patients who had taken anastrozole continued to show reduced rates of tumor recurrence and metastasis compared with patients who had taken tamoxifen. In fact, the relative benefit of anastrozole actually increased compared with results seen ...

Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases

... administered by intravenous or subcutaneous injections have shown clinical activity in a range of skeletal diseases, including hypercalcemia, bone metastasis (myeloma and breast cancer), Paget's disease, and osteoporosis. The initial clinical trial was a Phase 1 study of escalating single doses of G4544 ...

Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases

... sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In a Phase 2 trial in post- resection liver cancer, 160mg ...

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process

... create a lead antibody for pre- clinical development. LPA is a bioactive lipid long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types, as well as a significant contributor to neuropathic pain. "Humanizing our Lpathomab antibody is a vital next step ...

M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting

... of primary growth and distant metastasis with a CXCR4 antagonist in a mouse model of ... the ability of CTCE-9908 to inhibit the metastasis of a human breast cancer in preclinical models as ... also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in ...

Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients

... This binding process is believed to be critical in angiogenesis and in the metastasis (or spread) of cancer cells to distant locations in the body, where they ... repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of ...

Gentium's Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting

... 23, Tumor Biology 21, Abstract #3100, Board #29) Elevated heparanase expression in humans has been correlated with advanced progression and metastasis of many tumor types, including multiple myeloma (MM), where its presence may be particularly important because MM expresses high levels of ...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

... Southwestern. Number 2128: Blockade of tumor-derived VEGF activation of VEGF receptor 2 reduces macrophage infiltration into tumors and decreases metastasis in a pre-clinical orthotopic model of pancreatic cancer, Juliet G. Carbon, Shane E. Holloway, Andrew F. Miller, Anita Kavlie, Kyle Schlunegger, Jason ...

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

... poorest five-year survival rate. Liver cancer may be treated with surgery, radiation therapy or chemotherapy. The liver is also a common site for metastasis in other types of cancer, also known as secondary liver cancer. More than 500,000 people worldwide are diagnosed with secondary liver cancer each ...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

... with bevacizumab in breast cancer tumor models showed significantly enhanced anti-tumor response with a significantly reduced frequency of metastasis to the lymph nodes and lungs as compared to single agent therapy. (Abstract #2201; The Role of VEGF in Chemoprotection and Tumor Metastasis: ...

RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer

... that were consistent with healthy, cancer-free animals. "This paper provides important new data on how RTA 402 works to inhibit the growth and metastasis of cancer," said Warren Huff, CEO of Reata. "The effects on STAT3 shown in this paper, combined with the drugs' proven inhibition of NF-kB, indicate ...